American National Bank & Trust Sells 6,330 Shares of Boston Scientific Corporation $BSX

American National Bank & Trust lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 55.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,041 shares of the medical equipment provider’s stock after selling 6,330 shares during the quarter. American National Bank & Trust’s holdings in Boston Scientific were worth $492,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. FWL Investment Management LLC purchased a new position in Boston Scientific during the second quarter valued at approximately $26,000. Sound Income Strategies LLC boosted its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Steph & Co. bought a new position in Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. purchased a new position in shares of Boston Scientific during the 3rd quarter valued at $25,000. Finally, Kilter Group LLC bought a new position in shares of Boston Scientific in the second quarter worth $30,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 93,095 shares of company stock valued at $9,305,450 in the last 90 days. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.7%

Shares of Boston Scientific stock opened at $94.72 on Friday. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The company has a market capitalization of $140.42 billion, a P/E ratio of 50.65, a P/E/G ratio of 1.68 and a beta of 0.67. The company has a fifty day moving average of $97.92 and a 200 day moving average of $100.92.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Barclays lifted their price objective on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. UBS Group restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Morgan Stanley increased their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $124.85.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.